TY - JOUR
T1 - Development and Characterization of Three Recombinant Single Chain Antibody Fragments (scFvs) Directed against the CD19 Antigen
AU - Bejcek, Bruce E.
AU - Wang, Duo
AU - Berven, Erica
AU - Pennell, Christopher A.
AU - Peiper, Stephen C.
AU - Poppema, Sibrand
AU - Uckun, Fatih M.
AU - Kersey, John H.
PY - 1995/6/1
Y1 - 1995/6/1
N2 - Antibodies that recognize antigens restricted to leukemia, lymphoma, and normal hematopoietic cells represent a unique opportunity to develop therapeutics, because they have the potential for relatively selective treatment of these diseases. Antibodies that recognize the CD19 antigen found on normal and malignant B cells, but not on stem cells, have been used to develop immunoconjugates. However, these conjugates are large and might be suboptimal in tumor penetration when compared to molecules using smaller single chain Fv (scFv) antibody fragments. scFv has the advantage of being a molecularly engineered homogeneous molecule. In this report, we demonstrate the cloning, expression, and binding of three anti-CD19 antibodies as scFvs. All three scFvs were successfully cloned and expressed. FVS191, derived from ceU line B43, and FVS192, derived from SJ25C1, were properly refolded and bound CD19 antigen in FACS competition assays. These anti-CD19 scFv should be useful in the further development of diagnostic and therapeutic molecules.
AB - Antibodies that recognize antigens restricted to leukemia, lymphoma, and normal hematopoietic cells represent a unique opportunity to develop therapeutics, because they have the potential for relatively selective treatment of these diseases. Antibodies that recognize the CD19 antigen found on normal and malignant B cells, but not on stem cells, have been used to develop immunoconjugates. However, these conjugates are large and might be suboptimal in tumor penetration when compared to molecules using smaller single chain Fv (scFv) antibody fragments. scFv has the advantage of being a molecularly engineered homogeneous molecule. In this report, we demonstrate the cloning, expression, and binding of three anti-CD19 antibodies as scFvs. All three scFvs were successfully cloned and expressed. FVS191, derived from ceU line B43, and FVS192, derived from SJ25C1, were properly refolded and bound CD19 antigen in FACS competition assays. These anti-CD19 scFv should be useful in the further development of diagnostic and therapeutic molecules.
UR - http://www.scopus.com/inward/record.url?scp=0029033815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029033815&partnerID=8YFLogxK
M3 - Article
C2 - 7538901
AN - SCOPUS:0029033815
SN - 0008-5472
VL - 55
SP - 2346
EP - 2351
JO - Cancer Research
JF - Cancer Research
IS - 11
ER -